NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1211.20 -13.20 (-1.08%)

52W high on Jun 29, 2026

2.2M NSE+BSE Volume

NSE 17 Jul, 2026 3:31 PM (IST)

101,095.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Dr. Reddy's Labs is on 22 Jul 2026 for the purpose of Quarterly Results See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

15 Jul 2026

1211.20

-1.08%

Dr. Reddys Laboratories Ltd.– Q1FY27 Preview

Accumulate: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

We expect revenue at INR 81,451 Mn, as the quarter is likely to witness a normalization in the US business following the decline in Lenalidomide sales, which had been a key earnings driver over the last few quarters. The lower contribution from this high-margin product is expected to weigh on overall revenue growth.

Dr. Reddy's Laborato.. has an average target of 1350.33 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

10 Jul 2026

1211.20

-1.08%

Sema narrative weakens; more EPS cuts likely in the offing

Sell: Dr. Reddy's Laboratories Ltd.

Emkay

Dr Reddy's has disclosed that it has halted commercial supplies of Semaglutide with the recently scaled-up batch being found to be out of specification due to an issue associated with an impurity.

Deven Choksey decreased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1303.0 on 15 Jul, 2026.

Dr. Reddy's Laboratories Ltd.

10 Jul 2026

1211.20

-1.08%

Operational Setback, Structural Opportunity Intact

Not Rated: Dr. Reddy's Laboratories Ltd.

Deven Choksey

The disruption has come at a time when demand for semaglutide is very strong, making the timing particularly challenging.

Dr. Reddy's Laborato.. has an average target of 1350.33 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

09 Jul 2026

1211.20

-1.08%

Impurity-led delay impacts FY27 semaglutide volume

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

The delay in the commercial supply of semaglutide, due to an out-of-specification impurity issue in the semaglutide formulation, is expected to postpone the product ramp-up, with supplies likely to resume only by late Oct'26/early Nov'26.

Number of FII/FPI investors decreased from 855 to 849 in Mar 2026 qtr

Dr. Reddy's Laboratories Ltd.

01 Jul 2026

1211.20

-1.08%

Form 20-F – Lower bound set for the US base business

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

Dr Reddy’s’ Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~$300mn). However, assuming muted growth in the company’s base oncology portfolio since FY22, gRevlimid contribution would have been higher by ~$100mn in FY26 vs our base case.

Dr. Reddy's Laborato.. has an average target of 1350.33 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

18 May 2026, 12:00AM

1211.20

-1.08%

Outlook

Accumulate: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Deven Choksey

Overall, the company’s future potential is largely dependent on execution across GLP-1s, biosimilars, and differentiated product launches, along with its ability to stabilize the US business amid ongoing pricing pressure and gRevlimid erosion.

Dr. Reddy's Laborato.. has an average target of 1350.33 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

13 May 2026

1211.20

-1.08%

Dr. Reddy's Laboratories (DRRD IN) Q4FY26 Result Update Weak quarter; Scale up in Sema will be key Upgrade to ACCUMULATE'

Accumulate: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q4FY26 had several one offs including shelf stock adjustment of gRevlimid. Adjusted for this base business EBITDA were at INR12bn with ~15% OPM. This should pick up with Semaglutide launch across key markets along with moderation of overheads which will be key for margin recovery. Further timely launches like bAbatacept can accelerate profitability from H2FY28. Domestic and Russia sales continue to be on strong footing. We have scale up base business margins from the...

Number of FII/FPI investors decreased from 855 to 849 in Mar 2026 qtr

Dr. Reddy's Laboratories Ltd.

13 May 2026

1211.20

-1.08%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

Q4FY26- Revlimid void, one-off costs hurt numbers; Outlook optimisticQ4FY26 revenues de-grew 11.5% YoY to 7546.4 crore, pulled down significantly by the US business which de-grew 51% YoY to 1756 crore and PSAI which de-grew 4.5% YoY to 912 crore. The US business declined on account of lower gRevlimid sales and a one-time Shelf Stock Adjustment (SSA) of ~453 crore. The de-growth in US was stabilized by growth in other key geographies. Europe grew 14% YoY to 1452 crore (NRT portfolio in Europe grew 16% YoY to ~695 crore), India Business grew 20% YoY to 1566.3 crore, Russia and Other CIS business grew 19%...

Dr. Reddy's Laboratories Ltd. is trading below all available SMAs

Dr. Reddy's Laboratories Ltd.

23 Feb 2026

1211.20

-1.08%

DR. REDDY'S LABORATARIES

Hold: Dr. Reddy's Laboratories Ltd.

Recommendation Target

Geojit BNP Paribas

The North American business faced challenges, with revenue declining due to decreased Lenalidomide sales and increased price erosion for certain key products. Additionally, the delayed launch of biosimilars limited revenue growth during the quarter. However, Q3FY26 witnessed strong performance in India, Emerging markets, and the newly acquired consumer healthcare unit, which is focused on nicotine replacement therapy. The company aims to boost core business growth, advance patented products such as Semaglutide and Abatacept, improve operational...

Dr. Reddy's Laborato.. has an average target of 1350.33 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

23 Jan 2026

1211.20

-1.08%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

About the stock: Dr Reddy's (DRL) business encompasses generic formulations sales across US, Europe, RoW markets and branded generics in India and Russia CIS. The business also comprises of API sales under the head PSAI. The company...

Deven Choksey decreased Accumulate price target of Dr. Reddy's Laboratories Ltd. to 1303.0 on 15 Jul, 2026.

Is Dr. Reddy's Laboratories Ltd. worth buying?

551 Votes:

Buy 77.68%

Sell 12.7%

Hold 9.62%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf